Law Firm Investigates Fairness of Cross Country Healthcare's $13.25 Sale to Knox Lane

What happened

Cross Country Healthcare (CCRN) is being acquired by private equity firm Knox Lane for $13.25 per share in cash, but law firm Wohl & Fruchter has renewed its investigation into whether the price is fair to shareholders. The stock currently trades at $9.06, well below the offer, signaling market doubt about deal completion or the potential for a higher bid. The master report values CCRN at $7–15 per share depending on operating outcomes, with a base case of $12. The investigation adds another layer of uncertainty, potentially leading to a better offer or a failed deal. Investors should weigh the 46% premium against the risk of the deal collapsing and the stock falling back toward the bear case of $7.

Implication

The announcement of a law firm investigation into the Cross Country Healthcare sale at $13.25 per share introduces both upside and downside risk. The offer is substantially above the current $9.06 price, implying a 46% premium if the deal closes. However, the investigation could lead to delays, a higher offer, or deal termination. The master report's base case of $12 per share suggests the deal is slightly above fair value, but the bear case of $7 shows material downside if the deal fails and revenue continues to decline. Investors should monitor regulatory and legal developments closely. A successful close provides a quick gain, while a breakup could send shares to the upper single digits. Patience is warranted, but position sizing should account for the binary outcome.

Thesis delta

Previously, the investment thesis centered on Cross Country's balance sheet and potential for revenue stabilization over 6–12 months, with a base case of $12. Now, a definitive sale at $13.25 provides a near-term value floor, but the law firm investigation introduces deal risk and potential for a higher bid or collapse. The thesis shifts from waiting for operational recovery to navigating a binary event: the stock either converges to the offer price or falls back toward the bear case if the deal fails.